Posted by AGORACOM
at 8:31 PM on Monday, September 21st, 2020
Sweet Earth’s award-winning canine products will be sold under Thoughtful Brands’ Nature’s Exclusive brand, leveraging the Company’s eCommerce capabilities
VANCOUVER, BC / ACCESSWIRE / September 21, 2020 / Thoughtful Brands Inc. (CSE:TBI)(FWB:1WZ1)(OTCQB:PEMTF) (the “Company” or “Thoughtful Brands“), a global natural health products and eCommerce technology company, is excited to announce that the company has signed a Supply Agreement with Sweet Earth Holdings Corp. (CSE:SE) (FSE:1KZ1) (“Sweet Earth“), a vertically-integrated hemp company cultivating high-quality CBD products grown in Applegate Valley, Oregon. Sweet Earth is now officially the exclusive CBD dog treat provider to Thoughtful Brands’ direct to consumer brand, Nature’s Exclusive.
The agreement enables the Sweet Earth-produced CBD canine products to utilize Thoughtful Brands’ newly formed Ecommerce Tech LLC, a subsidiary operating a powerful ecommerce software platform designed to maximize customer acquisition and customer service.
The market for pet CBD products is booming: research sponsored earlier this year by RestoraPet and conducted by BDS Analytics and Arcview Market Research projects the pet CBD market to grow five percent faster than the overall CBD market over the next four years, from $64 million in 2018 to $810 million in 2024.
Sweet Earth canine products that will be sold under the Nature’s Exclusive brand include the popular Beef and Cheddar Potato CBD Dog Treats. Sweet Earth’s offerings are Leaping Bunny-certified, the gold-standard in cruelty-free certification for consumer goods signifying no new animal tests were conducted during product development.
“We are thrilled to be working with Sweet Earth, a renowned company whose sophisticated hemp-CBD offerings have long been celebrated,” said Thoughtful Brands CEO Ryan Dean Hoggan. “We are eager to propel the success of their CBD canine products by utilizing our global eCommerce platform and enhanced technology capabilities. We look forward to adding the brand to our portfolio and are hopeful for additional collaborations in the future.”
Building off the success of Nature’s Exclusive and the supply agreement with Sweet Earth, Thoughtful Brands is continuing to expand its portfolio in the nutraceutical and hemp-based CBD product space through the August 2020 acquisition of Golden Path LLC and Wild Mariposa LLC, two direct-to-consumer eCommerce brands offering natural health products throughout the U.S.
Sweet Earth’s CEO, Peter Espig, commented, “We are very excited to work closely with Thoughtful Brands, a company that we feel maintains the hemp industry’s premier brands. The company is well managed, maintains a powerful global platform and enhanced technological capabilities, and constantly researches for new methods of increasing customer service. We look forward to adding our products to Thoughtful Brand’s rapidly growing eCommerce platform, and are hopeful for future collaborations.”
In addition to the above, the Company announces the resignation of Szascha Lim as Chief Financial Officer. The role will be fulfilled once the appropriate person is found.
About Thoughtful Brands Inc.
Thoughtful Brands Inc. is an eCommerce technology company that researches, develops, markets, and distributes natural health products through various brands in North America and Europe. Through continuous strategic acquisitions, the Company has a strong footprint in the CBD market, as well as the burgeoning psychedelic medicine sector. Thoughtful Brands owns and operates a 110,000 square foot pharmaceutical manufacturing facility in Radebeul, Germany, where its highly skilled team conducts clinical studies utilizing naturally occurring psilocybin and other compounds found in psychedelics for the treatment of opiate addiction, while planning for future opportunities to create proprietary psilocybin products.
ON BEHALF OF THE BOARD OF DIRECTORS THOUGHTFUL BRANDS INC.
Ryan Hoggan Chief Executive Officer
For further information, readers are encouraged to contact Joel Shacker, President at +604.423.4733 or by email at [email protected]
Posted by AGORACOM-JC
at 9:27 AM on Monday, September 21st, 2020
Avicanna Rapid Act Spray
RHO Phyto™ Rapid Act Sprays are now available nationwide in high ratios of CBD to THC and are designed for rapid absorption and with lemon-mint flavour on the Medical Cannabis by Shoppers™ portal.
The Rapid Act Sprays are also available for the Medical Cannabis Real World Evidence Studies (MC-RWE) conducted by the University Health Network in partnerships with Medical Cannabis by Shoppers along side RHO Phyto’s Micro Drop Oil formulations.
TORONTO , Sept. 21, 2020 – Avicanna Inc. (” Avicanna ” or the ” Company “) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, is pleased to announce that its advanced RHO Phyto Rapid Act Sprays are now officially available nationwide in Canada on the Medical Cannabis by Shoppers (” Shoppers “) portal, as well as through the Medical Cannabis Real-World Evidence Study at the University Health Network.
Avicanna’s RHO Phyto product line is now commercially available after years of research and development through collaborations with world class academic and clinical organizations. The development of RHO Phyto products has focused on the key properties in drug development that health care providers seek when recommending a medical product to their patients such as formulation stability for consistent dosing, enhanced absorption and a range of onset times.
The Rapid Act Spray is a sublingual spray and is among the second set of Avicanna’s RHO Phyto products available for purchase through Shoppers. The sublingual sprays bypass first-pass metabolism and are quickly absorbed in the mucosal lining under the tongue. The RHO Phyto Rapid Act Spray provides an alternative delivery form to the RHO Phyto Micro Drops (also available for sale through Shoppers) which are absorbed through the oral route. The RHO Phyto Rapid Act Sprays have been formulated with specific ingredients that enhance absorption and the onset time of cannabinoids across the mucous membrane beneath the tongue. The lemon-mint flavoured sprays will be available in 10:20 CBD and 2:40 (w/w) THC to CBD ratios.
Dr. Justin Grant , Avicanna’s Executive Vice President of Scientific Affairs, commented, “The RHO Phyto Rapid Act Sprays are designed for faster onset and can be used in acute conditions where patients seek faster relief. The sublingual sprays can also be used to supplement slower and longer acting products, such as the RHO Phyto Micro Drop, when occasional higher doses may be required. Sublingual administration provides an alternative to the potentially harmful effects of consuming inhalation products.”
In August 2020 , Avicanna launched its blood orange flavoured RHO Phyto Micro Drop 2:50 CBD and Micro Drop 5:20 CBD. In the coming months, Avicanna will be launching its much-anticipated RHO Phyto Deep Tissue Gel, Daily Cream and Simple Dose Capsules. To ensure batch-to-batch consistency and high-quality products, these formulations are manufactured at MediPharm Labs Inc, a Good Manufacturing Practices (” GMP “) certified facility. In addition to strict GMP manufacturing, all RHO Phyto products undergo GMP-level analytical testing by Sigma Analytical Services Inc. and use blockchain technology developed by TruTrace Technologies Inc. to manage, track and trace each step of the supply chain.
Detailed guidelines outlining dosing and titration for Health Care Practitioners (” HCPs “) and patients is available on the RHO Phyto website at www.rhophyto.com . In addition, the Avicanna Academy includes additional product information for patients, frequently asked questions, and a recording of Avicanna’s 3rd annual symposium which was hosted virtually in partnership with Shoppers on July 21, 2020. For more information visit https://www.avicanna.com/the-avicanna-academy/ .
The Company has also re-branded and re-launched its subsidiary, My Cannabis Clinic (formerly known as My Cannabis), which specializes in assisting patients to gain access to medical cannabis and cannabinoid-based products for medical use. My Cannabis Clinic is devoted to providing HCPs and patients with the support and education needed for medical cannabis use. My Cannabis Clinic believes in providing quality care to patients and providing education on the considerations and potential benefits that cannabis has to offer for medical use. Information about My Cannabis Clinic can be found at https://mycannabisclinic.org/ .
About Avicanna
Avicanna is a diversified and vertically integrated Canadian biopharmaceutical company focused on the research, development, and commercialization of plant-derived cannabinoid-based products for the global consumer, medical, and pharmaceutical market segments.
Avicanna is an established leader in cannabinoid research and development, which it primarily conducts at its R&D headquarters in the Johnson & Johnson Innovation Centre, JLABS @ Toronto, Canada and in collaboration with leading Canadian academic and medical institutions. In addition to its developing pharmaceutical pipeline, Avicanna’s team of experts have developed and commercialized several industry leading product lines, including:
Pura H&W™: an advanced and clinically tested line of CBD consumer derma-cosmetic products; and,
RHO Phyto™: an advanced line of medical cannabis products containing varying ratios of CBD and THC currently available nation-wide across Canada in partnership with Medical Cannabis by Shoppers™, a subsidiary of Shoppers Drug Mart. RHO Phyto is the first strictly medical formulary of advanced “Cannabis 2.0” products, containing oils, sprays, capsules, creams, and gels, all developed with scientific rigour, manufactured under GMP standards and supported by pre-clinical data.
With ongoing clinical trials on its derma-cosmetic (Pura H&W), medical cannabis (RHO Phyto) and a pipeline of pharmaceutical products, Avicanna’s dedication to researching the important role that cannabinoids play in an increasingly wider scope of products has been at the core of the Company’s vision since its inception. Furthermore, Avicanna’s commitment to education is demonstrated through its annual medical symposium, the Avicanna Academy educational platform, and the My Cannabis Clinic patient program through its subsidiary company.
Avicanna manages its own supply chain including cultivation and extraction through its two majority-owned subsidiaries, Sativa Nativa S.A.S. and Santa Marta Golden Hemp S.A.S., both located in Santa Marta, Colombia. Through these sustainable, economical, and industrial scale subsidiaries, Avicanna cultivates, processes, and commercializes a range of cannabis and hemp cultivars dominant in CBD, CBG, THC, and other cannabinoids for use as active pharmaceutical ingredients. Avicanna’s Avesta Genetica program specializes in the development and optimization of rare cultivars for commercial production along with feminized seeds for global export. In June 2020, Avicanna made history with a shipment of hemp seeds to the United States of America by completing the first ever export of hemp seeds from Colombia.
SOURCE Avicanna Inc.
Stay Connected
For more information about Avicanna, visit www.avicanna.com , call 1-647-243-5283, or contact Setu Purohit , President by email at [email protected] .
Cautionary Note Regarding Forward-Looking Information and Statements
This news release contains “forward-looking information” within the meaning of applicable securities laws. Forward-looking information contained in this press release may be identified by the use of words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions, and includes statements with respect to the ability of the RHO Phyto Rapid Act Sprays to be used in acute conditions where patients seek faster relief, the ability of the RHO Phyto Rapid Act Sprays to be used to supplement slower and longer acting products, the ability of the Company launching the RHO Phyto Deep Tissue Gel, Daily Cream and Simple Dose Capsules , the ability of My Cannabis Clinic to provide HCPs and patients with the support and education needed for medical cannabis use, and that there is a benefit to using cannabis for medical purposes. Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment; and the availability of licenses, approvals and permits.
Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to current and future market conditions, including the market price of the common shares of the Company, and the risk factors set out in the Company’s annual information form dated April 15, 2020 , filed with the Canadian securities regulators and available under the Company’s profile on SEDAR at www.sedar.com .
The statements in this press release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.
Posted by AGORACOM
at 7:46 AM on Monday, September 21st, 2020
Agreement paves the way for Thoughtful Brands to become vertically integrated and subsequently reduce operating costs while expanding sales
VANCOUVER, BC / ACCESSWIRE / September 21, 2020 / Thoughtful Brands Inc. (CSE:TBI)(FSE:1WZ1)(OTCQB:PEMTF) (the “Company” or “Thoughtful Brands“), a global natural health products and eCommerce technology company, is pleased to announce that it has signed a binding term sheet to acquire (the “Proposed Acquisition“) all of the issued and outstanding shares, or all of the assets of, Kentucky-based hemp extraction company American CBD Extraction Corp. (“American CBD“). The Proposed Acquisition is expected to set the stage for Thoughtful Brands to become a fully vertically-integrated CBD company, controlling each aspect of the supply chain, including production, logistics and value chain.
Upon completion of the Proposed Acquisition, the Company will acquire an abundance of hemp biomass along with a fully equipped 41,000 square foot facility with the ability to process more than 1,200 pounds of hemp per day once licensed. Upon completion, Thoughtful Brands would also be able to utilize American CBD’s technological and scientific expertise to enhance the formulations of the Company’s various direct-to-consumer CBD brands, which include Nature’s Exclusive, Sativida and the recently acquired Golden Path and Wild Mariposa. Additionally, the Company plans to sell American CBD’s hemp biomass to support operations in Europe and to other clients worldwide.
“The term sheet with American CBD is an important milestone for the Company because it increases the likelihood of expanded margins and will allow us to launch innovative new products for which we control every step of the process,” said Thoughtful Brands CEO Ryan Hoggan. “Once we’re able to work directly with the team at American CBD and within their state-of-the-art Kentucky facility, we expect to be able to fine-tune and advance our cannabinoid product portfolio.”
Acquisition Details
The Company proposes to acquire all of the issued and outstanding share capital of, or all of the assets of, American CBD in consideration for Cdn$11,000,000, which will be satisfied through the issuance of common shares of the Company (the “Consideration Shares“). The Consideration Shares will be issued to the existing shareholders of American CBD or, in the case of an asset acquisition, directly to American CBD, at a deemed price equivalent to the lesser of (a) Cdn$0.18 per share or (b) the five-day volume-weighted average closing price of the Company’s common shares on the Canadian Securities Exchange for the period preceding closing of the Proposed Acquisition. The Consideration Shares shall be paid upfront and subject to an escrow arrangement, from which 25% of the Consideration Shares will be released on the closing date of the Proposed Acquisition, followed by an additional 25% after each subsequent 90-day period.
In addition to the Consideration Shares, a bonus of Cdn$1,000,000 will be paid to the operating team of American CBD on closing and a Cdn$2,000,000 performance milestone payment will be paid to the operating team of American CBD upon the achievement of production and cumulative online sales of over USD$1,000,000. The bonus and milestone shares will be payable in common shares of the Company based on the five-day volume weighted average closing price of the Company’s shares on the Canadian Securities Exchange immediately prior to the bonus and milestone payments becoming payable.
Closing of the Proposed Acquisition is subject to American CBD: (a) having a minimum cash balance of Cdn$2,000,000, less closing costs related to the Proposed Acquisition (which are not exceed Cdn$40,000); (b) having no debts or liabilities; and (c) having been granted a seat on the Company’s board of directors, all on the closing of the Proposed Acquisition.
The Company is at arms-length from American CBD and its shareholders. The transaction will not constitute a fundamental change for the Company, nor is it expected to result in a change of control of the Company, within the meaning of applicable securities laws and the policies of the Canadian Securities Exchange.
Readers are cautioned that the final terms and structure for a transaction between the Company and American CBD have not yet been determined. Completion of any transaction remains subject to negotiation of definitive documentation and satisfaction of conditions set forth above, as well as customary closing conditions for a transaction of this nature. The Proposed Acquisition cannot be completed until these conditions are satisfied. The Company will provide additional information regarding the Proposed Acquisition as soon as it becomes available.
About Thoughtful Brands Inc.
Thoughtful Brands Inc. is an eCommerce technology company that researches, develops, markets, and distributes natural health products through various brands in North America and Europe. Through continuous strategic acquisitions, the Company has a strong footprint in the CBD market, as well as the burgeoning psychedelic medicine sector. Thoughtful Brands owns and operates a 110,000 square foot pharmaceutical manufacturing facility in Radebeul, Germany, where its highly skilled team conducts clinical studies utilizing naturally occurring psilocybin and other compounds found in psychedelics for the treatment of opiate addiction, while planning for future opportunities to create proprietary psilocybin products.
About American CBD Extraction Corp.
From the rich soils of Kentucky, American CBD Extraction Corp. is a Kentucky-based company that produces cannabinoid distillates and isolates, and is positioned to become a significant supplier of hemp-derived extracts. Its location in the eastern part of Kentucky, a place that has been called “The Hemp Capital of the United States,” gives American CBD the privilege to partner with the state’s most experienced farmers to source the highest quality hemp for its products. American CBD is a company founded on dedication, strong work ethic and quality, fulfilling its mission to provide consistent, high-grade and clean hemp-derived CBD oil to meet the growing demand in this evolving marketplace.
ON BEHALF OF THE BOARD OF DIRECTORS
THOUGHTFUL BRANDS INC. Ryan Hoggan Chief Executive Officer
For further information, readers are encouraged to contact Joel Shacker, President at +604.423.4733 or by email at [email protected].
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this press release, which has been prepared by management.
Posted by AGORACOM
at 6:46 AM on Tuesday, September 15th, 2020
VANCOUVER, BC / ACCESSWIRE / September 15, 2020 / Thoughtful Brands, Inc. (CSE:TBI)(FWB:1WZ1)(OTCQB:PEMTF) (the “Company” or “Thoughtful Brands“), a global natural health products and eCommerce technology company, is pleased to report its financial results for August, July and June 2020. Revenue for the month of August totaled Cdn$3,809,000 with related expenses of Cdn$3,652,000, revenue for the month of July totaled Cdn$2,340,000 with related expenses of Cdn$2,418,000, and revenue for the month of June totaled $2,712,000 with related expenses of Cdn$2,775,000. Revenues generated during the period of June to August 2020 represents an increase of 19%, over the same period in 2019.
The Company’s August 2020 financial results follow recent strategic acquisitions, expansions into new marketplaces and strong sales performances from established brands:
In August 2020 Thoughtful Brands enhanced its portfolio in the nutraceutical and hemp-based CBD product space through the acquisition of Golden Path LLC and Wild Mariposa LLC, two direct-to-consumer eCommerce brands offering natural health products throughout the U.S.
In July 2020, the Company announced a European expansion through a joint venture with Franchise Cannabis Corp. Thoughtful Brands will now sell and market Franchise-manufactured CBD, hemp and cosmetic products in the European Union, Switzerland, Norway and the UK, utilizing its well-established eCommerce platform.
“By executing our meticulously planned growth strategy, the Company was positioned for a productive August and is poised to embark on even more new ventures for the remainder of 2020,” said Thoughtful Brands CEO Ryan Hoggan. “With new consumer brands on our roster and new customers abroad, there are plenty of activities in the Thoughtful Brands pipeline to look forward to.”
In addition, in August 2020 Thoughtful Brands launched Ecommerce Tech LLC (“Ecommerce Tech“), a new wholly owned subsidiary of the Company in the United States. Going forward, Ecommerce Tech will serve as the comprehensive operational engine for all Thoughtful Brands eCommerce ventures, paving the way for the Company to capture previously unrealized value from the products it launches in the online natural health market and launch new products in the emerging natural health markets worldwide more efficiently than before.
“Our powerful new software platform is another reason to eagerly anticipate what fall 2020 has in store for Thoughtful Brands,” added Hoggan.
The Company cautions that reported figures for revenue and expenses have not been audited and are based on calculations prepared by management. Actual results may differ from those reported in this release once these figures have been audited. These figures were translated from United States Dollars into Canadian Dollars using an exchange rate of $1.00 (US):$1.355 (Canadian) for June 2020, $1.00 (US):$1.3499 (Canadian) for July 2020, and $1.00 (US):$1.3222 (Canadian) for August 2020 .
About Thoughtful Brands Inc.
Thoughtful Brands Inc. is an eCommerce technology company that researches, develops, markets, and distributes natural health products through various brands in North America and Europe. Through continuous strategic acquisitions, the Company has a strong footprint in the CBD market, as well as the burgeoning psychedelic medicine sector. Thoughtful Brands owns and operates a 110,000 square foot pharmaceutical manufacturing facility in Radebeul, Germany, where its highly skilled team conducts clinical studies utilizing naturally occurring psilocybin and other compounds found in psychedelics for the treatment of opiate addiction, while planning for future opportunities to create proprietary psilocybin products.
ON BEHALF OF THE BOARD OF DIRECTORS THOUGHTFUL BRANDS INC.
Ryan Hoggan Chief Executive Officer
For further information, readers are encouraged to contact Joel Shacker, President at +604.423.4733 or by email at [email protected]
When we say vertically integrated, we mean it. Avicanna has 4 fully operating divisions to address the entire market for Cannabis products. As a Cannabis investor, why limit yourself to a Company with just one specialty, when Avicanna offers you exposure to the entire vertical.
CONSUMER RETAIL – COSMETICS
The Only Known CBD Cosmetics Backed By Clinical Trials
Full Line Of High End CBD Based Skin Care Products
Already Commercializing In Colombia
Global Distribution In H2 2020 In United States, Europe and Canada
Canadian Distribution Through Shoppers Drug Mart
MEDICAL CANNABIS
Medical Cannabis 2.0 – Superior Products To Products Currently On The Market
Evidence Backed Medical Cannabis So Doctors Can Prescribe With Confidence
Full Launch Across Canada Immanent
Exclusive Distribution Through Online Store Of Shoppers Drug Mart
RHO Phyto “Micro Drop” oil formulations are the first of the RHO Phyto formulary of advanced medical cannabis products available for patients and health care practitioners
Global Distribution Through US, U.K, Australia, Colombia and Canada In H2 2020
PHARMACEUTICALS
A Full Pipeline Of Pharmaceuticals In Various Stages Of Trials To Address Dermatology, Psychiatry, Neurology, Pain and Oncology
3 Products Already As Far As PHASE 2
CULTIVATION
500,000 Sq Ft Of Low Cost and USDA certified Organic Cannabis Cultivation In Colombia
First Ever Export Of Feminized Hemp Seeds From Colombia (To United States). 7,000,000 Seeds For $380,000
Additional 75,000,000 Seeds Available For Export In Several Pending Transactions
Posted by AGORACOM-JC
at 8:19 AM on Thursday, September 10th, 2020
Announced that Lyfted Farms Inc. (a wholly-owned subsidiary) has opened two banking accounts with a local California credit union based in Modesto, California
Credit union has agreed to open accounts to service both the Lyfted Farms licensed cannabis commercial activity and a second account for the Higher Standard Apparel Co., which merchandises Lyfted Farms Brand apparel@.
Lyfted Farms payroll and payments to vendors will now be dispatched through conventional banking methods via the credit union account and will require less time and expense to process
Vancouver, British Columbia–(September 10, 2020) – TransCanna Holdings Inc. (CSE: TCAN) (XETR: TH8) (“TransCanna” or the “Company”) TransCanna announces that Lyfted Farms Inc. (a wholly-owned subsidiary) has opened two banking accounts with a local California credit union based in Modesto, California.
The credit union has agreed to open accounts to service both the Lyfted Farms licensed cannabis commercial activity and a second account for the Higher Standard Apparel Co., which merchandises Lyfted Farms Brand apparel@.
The accounts are being opened to full-service all financial business needs after more than a year of due diligence on the part of the financial institution, including on-site visits to Lyfted Farms facilities, and will be operational by September 15th, 2020. Lyfted Farms payroll and payments to vendors will now be dispatched through conventional banking methods via the credit union account and will require less time and expense to process.
“We are pleased to be working with a local California based credit union as our financial services provider,” says Bob Blink, TransCanna CEO. “The organization has been servicing this community for decades and was founded by agricultural producers who, like us, live and work here, so we look forward to working with a respected organization that has the same level of appreciation for our market and our community as we do.”
Blink adds that the Federal prohibition on cannabis on the mainstream/non-credit union banking system has put a strain on legitimate businesses and that conducting large transactions in cash, as many licensed cannabis companies are forced to do, is a cumbersome and less secure process.
“Our growth is making banking a greater necessity with every passing day,” says Blink.”
The opening of the accounts represents historic firsts for both Lyfted Farms Inc., to have access to traditional banking services, and for a local California-based credit union to have a cannabis-based business client.
The Company further announces it has granted a total of 200,0000 incentive stock options to consultants involved in the development of the Company’s operations. The options are exercisable for a period of one year from the date of grant at an exercise price of $1.06 per common share in the capital of the Company.
The stock options are being granted pursuant to the terms of the Company’s stock option plan and are subject to regulatory approval.
About TransCanna Holdings Inc.
TransCanna Holdings Inc. is a California based, Canadian listed Company building cannabis-focused brands for the California lifestyle through its wholly-owned California subsidiaries.
On behalf of the Board of Directors Bob Blink, CEO 604-349-3011
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws or forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs regarding future events of management of the Company. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. This information and these statements referred to herein as “forward-looking statements”, are not historical facts, are made as of the date of this news release and include without limitation estimates and forecasts and statements as to management’s expectations for growth and the commencement of operations of the Company’s Daly facility.
The forward-looking information in this press release is based upon certain assumptions that management considers reasonable in the circumstances, including that operations will commence at the Company’s Daly facility in Modesto, California, as and when expected.
These forward-looking statements involve numerous known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially from any future results, events or developments expressed or implied by such forward-looking statements. Risks and uncertainties associated with the forward-looking information in this news release include, among others, dependence on obtaining and maintaining regulatory approvals, including state, local or other licenses and any inability to obtain all necessary governmental approvals licenses and permits to complete upgrades to its Daly facility in a timely manner; engaging in activities which currently are illegal under U.S. federal law and the uncertainty of existing protection from U.S. federal or other prosecution; regulatory or political change such as changes in applicable laws and regulations, including U.S. state-law legalization, particularly in California, due to inconsistent public opinion, perception of the medical-use and adult-use marijuana industry, bureaucratic delays or inefficiencies or any other reasons; any other factors or developments which may hinder market growth;; reliance on management; and the effect of capital market conditions and other factors (including those related to the COVID-19 pandemic) on capital availability; competition, including from more established or better financed competitors; and the need to secure and maintain corporate alliances and partnerships, including with customers and suppliers.
Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look, except in accordance with applicable securities laws.
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN
Posted by AGORACOM-JC
at 5:08 PM on Tuesday, September 8th, 2020
SPONSOR: Hollister Biosciences Inc. (HOLL:CSE) A vertically integrated Cannabis company with products in 230 California dispensaries, over 80 dispensaries throughout Arizona, joint ventures, licensing agreements and partnerships with Global brands. Revenue generated for the three-month period ended June 30th, 2020 was USD $8.47 million. Learn More
July Cannabis Sales Surge in 5 Western States
In July 2020, cannabis sales for state licensed retailers and delivery services reached $334.4 million, growing 15 percent from the trailing month and 26 percent compared to July 2019.
Year to date, sales in California have reached $1.9 billion, a 14 percent increase compared to the same period in 2019.
A Detailed Look at Cannabis Sales in California, Oregon, Arizona, Colorado and Nevada
Data provided by BDSA indicates that cannabis sales continued their robust expansion in 5 Western states. During July, the eleventh month after the onset of the vaping crisis and the fifth month of the pandemic impacting the market, sales across the five markets totaled $842.8 million, up 12% from June, which sequential increases of 2% in May and 14% in April. March had spiked to $666.0 million from $579.9 million in February as customers purchased cannabis ahead of store closures and concerns about limitations on access, so clearly cannabis sales are back on track. With the near-term effects of the pandemic now behind us, it’s clear that cannabis demand is surging, even in relatively mature markets, like Oregon and Colorado. Nevada continued to recover as tourism slowly returns, with sales growing 23%. California stood out with 15% sequential growth, while Colorado expanded 13%. Oregon sales climbed 6% and Arizona by 3%, but both of these states had meteoric growth from a year ago. July had one more day than June, which has the effect of adding 3% roughly.
Overall sales growth from a year ago among the five Western markets ranged from 26% in California to as high as 54% in Arizona. Nevada has been impacted by the tourist slowdown but still grew 37% from a year ago. Oregon continued its strong growth, rising 44%, while Colorado grew 35%. Concentrates represented 22-37% of sales by market, below the 26-38% share of sales last August before the vaping crisis hit.
Here is a closer look at each market, as detailed by BDSA:
Arizona
In July 2020, cannabis sales in Arizona’s medical dispensaries reached $94.2 million, growing three percent from June and over 54 percent compared to the previous July. Year-to-date through July, sales have reached $589.2 million, increasing by $194.5 million and 49 percent compared to the same period last year.
Flower sales accounted for nearly 48 percent of overall revenue for the month with $44.8 million in sales, growing one percent from June. Pre-rolled Joints, which are tracked as a separate category, accounted for just under four percent of revenue with $3.5 million in sales. Compared to the previous July, Flower sales increased by 52 percent and Pre-rolled Joints increased by 83 percent.
Concentrate sales accounted for about 37 percent of overall revenues with sales totaling $34.6 million in July, increasing six percent from the trailing month. Vape products, the largest segment of the Concentrates category, generated $21.8 million in sales, accounting for 63 percent of the Arizona Concentrates market and over 23 percent of sales across all categories. Compared to July 2019, sales of Dabbable Concentrates grew by 92 percent, while Vape sales grew by 46 percent.
The Ingestibles category accounted for nearly 11 percent of sales in July with $10 million in revenue for the month. Compared to July 2019 and June 2020, sales in the category grew by 47 percent and by four percent, respectively. In July, the $9.3 million in sales from Edibles generated nearly 93 percent of Ingestibles sales overall, while Sublinguals made up the remaining seven percent. Compared to the previous July, Edibles sales increased by 59 percent and Sublingual sales decreased by 30 percent.
California
BDSA sales reporting for the month of July reflects the state market of 699 licensed dispensary locations and 306 delivery operators.
In July 2020, cannabis sales for state licensed retailers and delivery services reached $334.4 million, growing 15 percent from the trailing month and 26 percent compared to July 2019. Year to date, sales in California have reached $1.9 billion, a 14 percent increase compared to the same period in 2019.
Sales from Flower generated $136.2 million in July 2020, accounting for nearly 41 percent of overall revenues. Compared to the trailing month and July 2019, Flower sales grew by 17 percent and 53 percent, respectively. Pre-rolled Joints, which are tracked as a separate category, accounted for nearly 11 percent of overall July revenues, with $35.6 million in sales.
Concentrates were the second-largest revenue category in July 2020, reaching $101 million in sales and accounting for over 30 percent of total revenue. Compared to the trailing month and July 2019, sales increased by 13 percent and by four percent, respectively. The $76 million in Vape sales accounted for over 75 percent of the Concentrates category and 23 percent of the month’s overall sales revenue.
In July 2020, Ingestibles generated $50.8 million in sales, increasing by 11 percent from the trailing month. Compared to July 2019, sales of Ingestibles grew by nearly 21 percent. Edibles contributed 86 percent of Ingestibles revenue, while Sublinguals made up the remaining 14 percent. Compared to July 2019, the Edibles and Sublinguals categories grew by 32 percent and declined by 22 percent, respectively.
Colorado
July 2020 was another milestone for the Colorado cannabis market. Sales in Colorado’s adult-use and medical dispensaries reached a combined $226.8 million, growing 13 percent from June. Compared to the previous July, sales increased by nearly 35 percent. Adult-use sales grew by 33 percent from July 2019 while medical sales grew by 41 percent. Year-to-date through July, combined channel sales have reached over $1.2 billion, increasing 22 percent from the same period last year.
In July, Flower sales accounted for over 47 percent of total monthly revenues, totaling at $107.2 million. Flower sales increased nearly 11 percent from the trailing month and grew 56 percent from the previous July. Year-to-date sales have increased by 40 percent in the category over the same period last year. Pre-rolled Joints, which are tracked separately from Flower, generated $13.2 million in sales for July 2020, growing 31 percent from July 2019 and increasing 17 percent from the trailing month.
The $66.5 million in Concentrate sales during July 2020 represented an 18 percent increase from the previous year and 15 percent growth from the trailing month. The category accounted for over 29 percent of revenue for the month. Vape products, the largest segment within the Concentrates category, reached $32.9 million in July sales, increasing 19 percent compared to June and four percent from the previous July, respectively. The Vape category accounted almost 50 percent of Concentrates’ revenue and 15 percent of overall sales for the month.
In July 2020, sales from Ingestibles generated $34.7 million, a 27 percent increase from July 2019. Compared to the trailing month, sales in the category grew by 17 percent. Edibles generated $32.7 million in monthly sales revenue, contributing over 94 percent to category sales and 14 percent of total revenue for the month. Sublinguals made up the remaining six percent of Ingestibles sales, totaling $1.9 million for the month.
Nevada
In July, Nevada dispensaries generated $82 million in sales. Compared to July of 2019, sales grew by 37 percent and by nearly 23 percent compared to the trailing month. Year-to-date through July, sales have reached $421.9 million, growing by six percent compared to the same period last year.
Flower sales accounted for nearly 54 percent of overall July 2020 sales. Sales in the category reached $44.1 million for the month, growing 27 percent from June. Pre-rolled Joints, tracked separately from Flower, accounted for nearly 11 percent of July sales, with $8.8 million in revenue. Compared to July 2019, Flower and Pre-rolled Joints sales have increased by 75 percent and by two percent, respectively.
Concentrate sales in July reached $18.3 million, accounting for more than 22 percent of overall revenue for the month. Compared to the trailing month as well as to the previous July, category sales increased by 17 percent. Vape products, the largest segment in the Concentrates category, generated $13.3 million for the month, contributing nearly 73 percent to Concentrates revenue and over 16 percent to total monthly sales.
Sales in the Ingestibles category accounted for 11 percent of all revenues, totaling $9.1 million in July sales and growing by about seven percent from the previous year. Compared to June, category sales grew by 17 percent. Edibles made up 90 percent of the Ingestibles category, reaching $8.2 million in July revenue, and Sublingual sales contributed the remaining ten percent.
Oregon
In July 2020, cannabis sales in Oregon’s medical and adult-use dispensaries reached a combined $106 million. Compared to the trailing month, sales in the Oregon market grew by about six percent, while compared to July 2019, sales grew by 45 percent overall. Year-to-date sales in Oregon have reached $620.3 million, growing by 39 percent compared to the same period in 2019.
Sales of Flower generated $50.3 million in July 2020, accounting for 47 percent of overall revenues. Compared to the trailing month, Flower sales grew by four percent, and compared to July 2019, sales increased by 65 percent. Pre-rolled Joints, which are tracked as a separate category, accounted for nine percent of overall revenues with $9.8 million in sales.
Concentrates generated $27.7 million in July sales. Compared to the trailing month and July 2019, sales in the category increased five percent and just over 25 percent, respectively. Vape products, the largest segment in the Concentrates category, generated $15 million in July, contributing over 54 percent of Concentrates sales and more than 14 percent of total monthly revenue.
In July 2020, Ingestibles generated over $14.6 million in sales, a nine percent increase from the previous month and nearly 25 percent compared to July 2019. Edibles, which made up 83 percent of the Ingestibles category and more than 11 percent of overall monthly sales, generated $12 million in July 2020.
For readers looking for a deeper look at cannabis markets across these five states and more, including segmentation by additional product categories, brand and item detail, longer history, and segmentation by product attributes, learn how the BDSA GreenEdge Platform can provide you with unlimited access to the most accurate and actionable data and analysis.
Posted by AGORACOM
at 9:01 AM on Tuesday, September 8th, 2020
Formed a joint venture with Franchise Cannabis Corp. to sell and market Franchise-manufactured CBD, hemp and cosmetic products in the European Union, Switzerland, Norway and the United Kingdom
VANCOUVER, BC / ACCESSWIRE / September 8, 2020 / Thoughtful Brands Inc. (CSE:TBI FWB: 1WZ1; OTCQB: PEMTF) (the “Company” or “Thoughtful Brands“), a global natural health products and eCommerce technology company, is pleased to announce the formation of its joint venture with Franchise Cannabis Corp. (“Franchise“) to sell and market Franchise-manufactured CBD, hemp and cosmetic products in the European Union, Switzerland, Norway and the United Kingdom (the “JV Territory“).
The parties’ will share equal ownership in the joint venture. Franchise will manage procurement and fulfillment of customer orders from its European manufacturing facilities. Thoughtful Brands will provide marketing and eCommerce operations infrastructure in the JV Territory.
Franchise is a leading European-focused cannabis and pharmaceutical distribution company based in Germany with two Good Distribution Practices (GDP) certified distribution facilities, exporting to over 18 countries and currently serving a network of over 1,500 pharmacies within Germany for medical cannabis sales.
“The Thoughtful Brands agreement with Franchise ensures we are in a strong position to continue our European expansion,” said Thoughtful Brands CEO Ryan Dean Hoggan. “Our marketing expertise coupled with Franchise’s procurement and distribution facilities will allow us to grow our customer base and generate significant sales with good margins. This joint venture also enables Thoughtful Brands to duplicate the model that has made us so successful in the United States.”
Pursuant to the Transaction Agreement, Franchise has agreed to make a $500,000 equity investment into the Company through a private placement subscription of $0.20 units (the “Units“). Each Unit will consist of one (1) common share of Thoughtful Brands (each, a “Share“) and one (1) Share purchase warrant (each, a “Warrant“), with each Warrant entitling the holder to purchase one additional Share (each, a “Warrant Share“) at a price of $0.28 per Warrant Share for a period of twenty-four (24) months from their date of issue. Thoughtful Brands will then make a $350,000 equity investment into the joint venture, which will be used to develop business operations, including the initial funds to launch Franchise products in Europe using the Company’s advanced eCommerce capabilities. The Units will be subject to a four-month-and-one-day statutory hold period in accordance with applicable securities laws.
About Thoughtful Brands Inc.
Thoughtful Brands Inc. is an eCommerce technology company that researches, develops, markets, and distributes natural health products through various brands in North America and Europe. Through continuous strategic acquisitions, the Company has a strong footprint in the CBD market, as well as the burgeoning psychedelic medicine sector. Thoughtful Brands owns and operates a 110,000 square foot pharmaceutical manufacturing facility in Radebeul, Germany, where its highly skilled team conducts clinical studies utilizing naturally occurring psilocybin and other compounds found in psychedelics for the treatment of opiate addiction, while planning for future opportunities to create proprietary psilocybin products.
ON BEHALF OF THE BOARD OF DIRECTORS
THOUGHTFUL BRANDS INC. Ryan Hoggan Chief Executive Officer
For further information, readers are encouraged to contact Joel Shacker, President at +604.423.4733 or by email at [email protected]
Posted by AGORACOM-JC
at 9:13 PM on Monday, September 7th, 2020
The Tortoise and the Hare is the famous fable most of us grew up with that teaches this very important lesson – you can be more successful by doing things slowly and steadily than by acting quickly and carelessly. Said another way, slow and steady wins the race.
Avicanna (AVCN:TSX) (AVCNF:OTCQB) (0NN:Frankfurt) is the Hare. The company very few paid attention to because it started off the Cannabis stock market race slowly and surely, while all the other rabbits ran so quickly to win the race that they ended up tripping over themselves or getting so exhausted they couldn’t finish the race.
You know who those companies are. All flash, big promises, big promotions, big stock prices ….. and HUGE disappointments.
Avicanna has surpassed all of them and is starting to pick up speed. When Avicanna says it is vertically integrated, it isn’t a buzz word, it’s the real story with 4 fully operating divisions that are hitting on all cylinders including, Tier-1 National Partnerships, Global Distribution, Medical Acceptance and History Making Sales.
Here is a snapshot of what we are referring to, followed by an incredible interview with CEO, Aras Azadian, whose quiet confidence sends the following powerful message –
“Watch Us Cross The Finish Line”
CONSUMER RETAIL – COSMETICS
The Only Known CBD Cosmetics Backed By Clinical Trials
Full Line Of High End CBD Based Skin Care Products
Already Commercializing In Colombia
Global Distribution In H2 2020 In United States, Europe and Canada
Canadian Distribution Through Shoppers Drug Mart
MEDICAL CANNABIS
Medical Cannabis 2.0 – Superior Products To Products Currently On The Market
Evidence Backed Medical Cannabis So Doctors Can Prescribe With Confidence
Successfully launched advanced products under RHO Phyto™ brand nation-wide in Canada through Medical Cannabis by Shoppers™, a subsidiary of Shoppers Drug Mart
Global Distribution Through US, U.K, Australia, Colombia in H2 2020
PHARMACEUTICALS
A Full Pipeline Of Pharmaceuticals In Various Stages Of Trials To Address Dermatology, Psychiatry, Neurology, Pain and Oncology
3 Products Already As Far As PHASE 2
CULTIVATION
500,000 Sq Ft Of Low Cost and USDA certified Organic Cannabis Cultivation In Colombia First Ever Export Of Feminized Hemp Seeds From Colombia (To United States).
7,000,000 Seeds For $380,000Additional 75,000,000 Seeds Available For Export In Several Pending Transactions
Q2 HIGHLIGHTS
Revenue increased 172% from $260,903 in Q1 2020 to $709,468 in Q2 2020, and a substantial increase from $16,571 in Q2 2019, coupled with 8% cost reduction from Q1 2020, and 31% cost reduction from Q2 2019
Posted by AGORACOM
at 9:05 AM on Friday, September 4th, 2020
An eCommerce company specializing in natural health products chronicles latest revenue, strategic acquisitions and partnerships, expansion and trajectory
During a period of three months that ended June 30, 2020, the Company recorded revenue of $12,842,934
VANCOUVER, BC / ACCESSWIRE / September 4, 2020 / Global natural health products and eCommerce technology company Thoughtful Brands Inc. (CSE:TBI)(FSE:1WZ1)(OTCQB:PEMTF) (the “Company” or “Thoughtful Brands“), which recently changed its name from Mota Ventures Corp. to better reflect the Company’s long-term growth strategy, is proud to announce its second quarter 2020 earnings results, as reported on August 31, 2020.
During a period of three months that ended June 30, 2020, the Company recorded revenue of $12,842,934, which was primarily due to the operations and strong sales performances of the Nature’s Exclusive CBD brand, whose product line led to a major sales boost amid the COVID-19 pandemic. Cost of goods sold amounted to $11,293,727 during the three months ended June 30, 2020. Cost of goods sold included costs for product fulfillment, as well as eCommerce campaign costs including customer acquisition. Revenues grew by 68% in the second quarter. Customers acquired for the twelve months ended June 30, 2020 reached 202,564 up from 44,207 compared with the twelve months ended June 30, 2019. Gross margin in Q2 2020 increased to 12%, as compared to gross margin in Q1 2020 of 8%, due to increased efficiencies in operations and increased customer acquisition due to online marketing campaigns in the current period.
“The Thoughtful Brands team would like to emphasize the Company’s commitment to its partners, the integral role of supply chain across its businesses, and its unrelenting effort to provide the best possible experience for its customers,” said CEO Ryan Hoggan. “Each of the ventures outlined below is part of our broader expansion plan and we’re looking forward to the remainder of 2020 and beyond.”
Key Highlights for the six months ended June 30, 2020
Financing
In April 2020, the Company completed a non-brokered private placement for gross proceeds of $4.5 million.
Acquisitions & Joint Ventures
On June 1, 2020 the Company completed its acquisition of Verrian, which owns and operates a 110,000 square foot pharmaceutical manufacturing facility in Radebuel, Germany. Operations within this full suite pharmaceutical manufacturing site include analytical laboratory and finished dose manufacturing, which exceed all international quality standards. The facility and equipment of Verrian have been independently appraised at Cdn$10,600,000 and include an analytical laboratory and full pharmaceutical manufacturing suite. Verrian also specializes in the development of psychedelic-derived medicines with the goal of formulating treatments for addictions-including opioids and alcohol. The move propelled Thoughtful Brands into the burgeoning psychedelic market and supports the Company’s forays into the natural health sector beyond the cannabidiol (“CBD“) market.
On April 7, 2020 the Company acquired a 20% ownership interest in Folium Life Sciences Inc., a Health Canada-licensed cannabis cultivator. Folium is expanding its licensed indoor cannabis production facility on Vancouver Island to produce a high quality and consistent cannabis product on site.
On March 25, 2020 the Company, through its Spanish subsidiary Global Zifar S.L., acquired the intellectual property and trade names of “Sativida” in Spain, and will license both back to Sativida in exchange for a royalty associated with the gross revenues generated by Sativida. Sativida is a producer and online retailer of CBD and branded CBD products in certain jurisdictions in Europe, including Spain, Portugal, Austria, Germany, France and the UK. Sativida is also the top search-ranked online retailer of CBD products in Spain and Mexico and plans to continue expanding its footprint in Europe and Latin America.
On January 17, 2020 Thoughtful Brands completed its acquisition of First Class CBD (which was re-branded as Nature’s Exclusive on April 6, 2020), an online direct-to-consumer retail distributor in the United States. Nature’s Exclusive offers a CBD hemp-oil formula intended to provide users with the therapeutic benefits that hemp-derived CBD may offer. The hemp oil used in the products is derived from hemp grown and cultivated in the United States. The extraction process is designed to maintain all the beneficial qualities that hemp may offer. Natures Exclusive offers a range of products, which include CBD oil drops, CBD gummies, CBD pain relief cream and CBD skin serum.
In January 2020, the Company’s wholly-owned subsidiary Ihuana S.A.S entered into a research cooperation agreement with La Fundacion Universitaria de Ciencias de la Salud (The University Foundation of Health Sciences) located in Bogota, Colombia. Pursuant to the agreement with the university, the parties agreed to engage in research and formulation of medicinal products made with non-psychoactive cannabis and cannabis byproducts.
In January 2020, Ihuana completed its 2,000 square foot research and development facility in Guasca, Colombia. The purpose-built R&D facility is for a seed registration program on Ihuana’s licensed land. This was a significant step, as it allows Ihuana to register the genetics of its high-CBD, low-THC strains of cannabis with the Colombian Agricultural Institute (Instituto Colombiano Agroprecuario, or ICA).
Key highlights subsequent to June 30, 2020
On August 22, 2020, the Company, through its wholly-owned US subsidiary, Ecommerce Tech LLC, acquired the rights to an eCommerce software platform from Unified Funding LLC’s wholly-owned subsidiary, Offer Space LLC. Prior to the Software acquisition, the Software was being used by the Company’s Nature’s Exclusive brand, and by the newly acquired brands, Golden Path and Wild Mariposa, through service agreements with Offer Space. The acquisition of the asset provides the Company with the opportunity to capture previously unrealized value from the products it launches in the online natural health market. The Software facilitated over Cdn$350 million in consumer transactions, including Cdn$93.8 million in 2019. The asset enhances the management of the Company’s already profitable online brands, and allows the Company to launch new products and enter into emerging natural health markets worldwide, more efficiently.
On August 19, 2020, the Company acquired Golden Path LLC and Wild Mariposa LLC, two direct-to-consumer eCommerce brands offering a range of natural health products, including nutraceutical and hemp-based CBD, within the United States. Every product manufactured is third-party tested for purity and manufactured in the United States in GMP certified facilities. The acquisitions expanded the Company’s portfolio in the nutraceutical and hemp-based CBD product space.
On July 21, 2020, the Company entered into a binding agreement with Franchise Cannabis Corp. to form a joint venture in Europe to sell and market Franchise-manufactured CBD, hemp and cosmetic products in the European Union, Switzerland, Norway and the United Kingdom. Sales of the custom-manufactured products will be sold online utilizing the Company’s eCommerce infrastructure.
Franchise is a European-focused cannabis and pharmaceutical distribution company based in Germany with two Good Distribution Practices (GDP) certified distribution facilities, exporting to over 18 countries and currently serving a network of over 1,500 pharmacies within Germany for medical cannabis sales.
About Thoughtful Brands Inc.
Thoughtful Brands Inc. is an eCommerce technology company that researches, develops, markets, and distributes natural health products through various brands in North America and Europe. Through continuous strategic acquisitions, the Company has a strong footprint in the CBD market, as well as the burgeoning psychedelic medicine sector. Thoughtful Brands owns and operates a 110,000 square foot pharmaceutical manufacturing facility in Radebeul, Germany, where its highly skilled team conducts clinical studies utilizing naturally occurring psilocybin and other compounds found in psychedelics for the treatment of opiate addiction, while planning for future opportunities to create proprietary psilocybin products.
ON BEHALF OF THE BOARD OF DIRECTORS THOUGHTFUL BRANDS INC.
Ryan Hoggan Chief Executive Officer
For further information, readers are encouraged to contact Joel Shacker, President at +604.423.4733 or by email at [email protected]
